| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Product | NaN | 5,420 | NaN | NaN |
| License And Service | NaN | 2,276 | NaN | NaN |
| Revenue | NaN | 6,161 | NaN | NaN |
| Cost of product revenue | NaN | 1,076 | NaN | NaN |
| Paltusotine | NaN | 118,889 | NaN | NaN |
| Atumelnant | NaN | 82,113 | NaN | NaN |
| Other research and development programs | NaN | 33,322 | NaN | NaN |
| Research and development personnel expenses | NaN | 179,504 | NaN | NaN |
| Research and development stock-based compensation | NaN | 88,265 | NaN | NaN |
| Other research and development | NaN | 51,042 | NaN | NaN |
| Total research and development expenses | NaN | 579,063 | NaN | NaN |
| External selling, general and administrative expenses | NaN | 90,013 | NaN | NaN |
| Selling, general and administrative personnel expenses | NaN | 103,135 | NaN | NaN |
| Selling, general and administrative stock-based compensation | NaN | 72,063 | NaN | NaN |
| Selling, general and administrative | NaN | 328,964 | NaN | NaN |
| Total other income, net | NaN | 11,031 | NaN | NaN |
| Income tax expense | NaN | 180 | NaN | NaN |
| Loss on equity method investment | NaN | 0 | NaN | NaN |
| Accretion of purchase discounts and amortization of premiums on investment securities, net | NaN | 0 | NaN | NaN |
| Net loss | -127,845 | -122,815 | -130,091 | -212,411 |
| Loss on equity method investment | NaN | 0 | 0 | 0 |
| Stock-based compensation | 29,680 | 21,720 | 22,702 | 46,602 |
| Depreciation and amortization | 1,160 | 994 | 1,012 | 1,884 |
| Noncash lease expense | 703 | 654 | 2,360 | NaN |
| Accretion of purchase discounts and amortization of premiums on investment securities, net | 2,220 | 2,734 | 3,601 | 9,090 |
| Loss on disposal of property and equipment | -20 | -8 | 0 | -42 |
| Trade accounts receivable | 5,091 | 592 | NaN | NaN |
| Inventory | 909 | 2,022 | NaN | NaN |
| Prepaid expenses and other assets | 7,024 | -2,020 | 7,206 | 11,325 |
| Deferred revenue | NaN | NaN | NaN | 984 |
| Accounts payable and accrued expenses, compensation and related expenses, and other liabilities | -12,064 | 11,176 | 6,647 | 11,160 |
| Noncash lease expense | NaN | NaN | NaN | 1,605 |
| Deferred revenue | -428 | -707 | -1,128 | NaN |
| Operating lease liabilities | -685 | -603 | -792 | -1,786 |
| Net cash used in operating activities | -124,703 | -92,901 | -110,718 | -174,303 |
| Purchases of investment securities | 554,428 | 213,646 | 216,700 | 574,081 |
| Purchase of radionetics preferred stock | NaN | 0 | NaN | NaN |
| Proceeds from sales and maturities of investment securities | 302,889 | 271,211 | 382,372 | 530,514 |
| Purchases of property and equipment | 820 | 458 | 863 | 4,441 |
| Net cash used in investing activities | -252,359 | 57,107 | 164,809 | -48,008 |
| Proceeds from issuance of common stock, net of commissions | 380,514 | 0 | 0 | 0 |
| Offering costs related to issuance of common stock | 578 | 0 | 0 | 0 |
| Proceeds from exercise of stock options and shares issued under employee stock purchase plan | NaN | 40,611 | NaN | NaN |
| Proceeds from exercise of stock options | -4,637 | NaN | 3,084 | 11,492 |
| Net cash provided by financing activities | 389,875 | 26,035 | 3,084 | 11,492 |
| Net change in cash, cash equivalents and restricted cash | 12,813 | -9,759 | 57,175 | -210,819 |
| Exchange rate changes in cash, cash equivalents and restricted cash | -8 | -106 | NaN | NaN |
| Cash, cash equivalents and restricted cash - beginning of period | 102,336 | 112,201 | 265,845 | NaN |
| Cash, cash equivalents and restricted cash - end of period | 115,141 | 102,336 | 112,201 | NaN |
Crinetics Pharmaceuticals, Inc. (CRNX)
Crinetics Pharmaceuticals, Inc. (CRNX)